HomeAI · summaries
Storia in 11 fonti
What's the deal with peptides? The hyped market under U.S. review
Explore the controversial rise of peptides, their FDA review, and concerns over safety and clinical evidence in wellness trends.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
nbcnews.com
What to know about the seven peptides an FDA advisory panel is set to review this week
The committee will discuss whether compounding pharmacies can make the peptides in question. But FDA scientists say there’s little — if any — evidence they work in humans.
- ·
fortune.com
The FDA’s peptide vote could create telehealth's next multibillion-dollar market | Fortune
As regulators weigh whether pharmacies can legally compound wellness peptides, companies are preparing for a repeat of the GLP-1 boom—only this time with even murkier science.
- ·
forbes.com
FDA’s Review Of Peptides Signals A Growing Public Health Challenge
A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.
- ·
npr.org
Peptides get their regulatory closeup
A panel of advisers to the Food and Drug Administration will meet this week to make recommendations on whether specialized pharmacies should be allowed to make some popular…
- ·
FDA Set To Review Safety And Access To Peptides: What You Need To Know
An FDA panel is reviewing seven peptides for potential approval, sparking concerns about their widespread use in compounding pharmacies and the gray market.
- ·
Peptides May Soon Be Legal. These Companies Are Ready To Cash In
With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming…
- ·
cbc.ca
U.S. FDA panel to review 7 peptides amid growing popularity | CBC News
U.S. FDA advisers this week will weigh whether seven popular peptides can be compounded by licensed pharmacies, but even if regulators decline to expand access, industry…
- ·
cnn.com
The future of peptides in the US is about to become clearer. Here’s what you should know | CNN
A little-known advisory group to the US Food and Drug Administration will meet this week to mull over whether to ease restrictions on certain peptides. The injectables are popular…
- ·
aljazeera.com
US regulators to weigh controversial peptides backed by RFK Jr
FDA has questioned the evidence as demand surges for the compounds promoted for sleep, muscle growth, and anti-ageing.
- ·
FDA panel considers easing peptide restrictions
Advisers to the Food and Drug Administration are weighing the evidence for seven different peptides. Favorable votes would pave the way for easier access.
- ·
independent.co.uk
FDA reviews peptide injections favored by RFK Jr. and wellness influencers
Federal health advisers are meeting to review a group of controversial chemicals called peptides
- ·
iol.co.za
What's the deal with peptides? The hyped market under US review
The substances under review -- including BPC-157, TB-500 and Semax -- are among those Joe Biden's administration restricted from compounding, notably over lack of human clinical…
- ·
thehindu.com
What's the deal with peptides? The hyped market under U.S. review
Explore the controversial rise of peptides, their FDA review, and concerns over safety and clinical evidence in wellness trends.
- ·
statnews.com
FDA staff and peptide enthusiasts set to clash at advisory panel
FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.